Spring Bank Pharmaceuticals Abstracts on STING Agonist SB 11285 Accepted for Poster Presentations at AACR Special Conference on Tumor Immunology and Immunotherapy

HOPKINTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced that two abstracts related to SB 11285, the Company’s novel, proprietary STING agonist compound for immuno-oncology, have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy taking place on October 20-23, 2016 at the Boston Marriott Copley Place in Boston, MA. These abstracts highlight the potent immune-modulating and anti-tumor activities of SB 11285 in multiple in vitro systems.

The titles of the Spring Bank poster presentations are as follows:

  1. Nucleotide Analogs as Novel STING Agonists for Immuno-oncology
  2. Novel dinucleotides that activate STING signaling for Immuno-oncology

Further details about the dates and times, abstract numbers, and locations for the poster presentations will be provided when these details are made available by AACR. 

About the American Association for Cancer Research

The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus.

CONTACT: Contact:
Jon Freve
Chief Financial Officer
(508) 500-4956